LennemanAJWangLWiggerM, et al.Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy. Am J Cardiol2013; 111: 609–612.
2.
LymanGHDaleDCFriedbergJ, et al.Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol2004; 22: 4302–4311.
3.
LennemanCGSawyerDB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ Res2016; 118: 1008–1020.
4.
RenuKVG APB T, et al.Molecular mechanism of doxorubicin-induced cardiomyopathy - An update. Eur J Pharmacol2018; 818: 241–253.
5.
D’Ascenzi F, Anselmi F, Fiorentini C, et al. The benefits of exercise in cancer patients and the criteria for exercise prescription in cardio-oncology. Eur J Prev Cardiol. Epub ahead of print 6 October 2019. DOI: 10.1177/2047487319874900.
6.
HowdenEJBigaranABeaudryR, et al.Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients. Eur J Prev Cardiol2019; 26: 305–315.
7.
IwabuchiKVan KaerL. Role of CD1- and MR1-restricted T cells in immunity and disease. Front Immunol2019; 10: 1837–1837.
8.
SobirinMAKinugawaSTakahashiM, et al.Activation of natural killer T cells ameliorates postinfarct cardiac remodeling and failure in mice. Circ Res2012; 111: 1037–1047.
9.
FeridooniTHotchkissARemley-CarrS, et al.Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes. PLoS One2011; 6: e22801–e22801.
10.
Barrera-ChimalJEstrelaGRLechnerSM, et al.The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int2018; 93: 1344–1355.
